Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Dec:30:197-200.
doi: 10.1016/j.breast.2016.06.016. Epub 2016 Jul 9.

SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes

Corrado Tinterri  1 , Giuseppe Canavese  1 , Paolo Bruzzi  2 , Beatrice Dozin  3
Affiliations
Randomized Controlled Trial

SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes

Corrado Tinterri et al. Breast. 2016 Dec.

Abstract

Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim.

Keywords: Axillary lymph node dissection (ALND); Breast cancer; Overall survival (OS); SINODAR ONE; Sentinel lymph node biopsy (SLNB).

PubMed Disclaimer

Publication types

LinkOut - more resources